Pneumagen’s lead product, Neumifil™, is a first-in-class mCBM40 being developed for the universal treatment of Influenza Virus (IFV), Respiratory Syncytial Virus (RSV) and COVID-19. Neumifil™ has the potential to revolutionise the treatment of RTIs by providing clinicians with the opportunity to offer their patients pan-viral protection, thus overcoming the limitations of current vaccines and other therapeutic approaches.
Neumifil – A sialidase-derived CBM40 from Streptococcus pneumoniae engineered to create multivalent high-affinity hexamers
When administered intranasally in preclinical models, Neumifil™ has demonstrated prevention, treatment and post-exposure prophylaxis of IFV infection with no observed toxicity. Neumifil™ has also been shown to be effective in other viruses, such as Respiratory Syncytial Virus (RSV), parainfluenza, and COVID-19 and is also under development for these indications.
Pneumagen is undertaking preclinical activities in COVID-19. This will be followed by a First-In-Human clinical trial with the goal of providing the earliest clinical data.
Neumifil™ will be administered intranasally. It will be developed for those at high-risk of severe RTI infection such as the elderly, immuno-compromised diabetic and those with underlying lung disease such as asthma and COPD.
Pneumagen is not recruiting volunteers for studies on coronavirus at the moment. This is a line of clinical research we are following and we will make announcements when we are ready to start recruitment.